Roth Capital analyst George Kelly initiated coverage of Beauty Health (SKIN) with a Buy rating and $3.50 price target The firm is positive on the company’s turnaround efforts and believes consensus estimates are too low given the opportunity for more cost-cutting. Further, Beauty Health’s growth can improve with the launch of new products in the second half of 2025 and 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKIN:
- Beauty Health launches Hydrafacial Advisory Councils, Ambassador Network
- Beauty Health Modifies Indenture for Convertible Notes
- Beauty Health Co. Earnings Call Highlights Strong Performance
- Restrictive Covenants in Beauty Health’s 2028 Notes: A Barrier to Growth and Flexibility
- Cautious Hold Rating on Beauty Health Amid Economic Challenges and Strategic Adjustments